GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy

Molecular Biology Reports

Volumn 40, Issue 11, 2013, Pages 6397-6405

  Wei, Hongshan ^a   Hao, Xiaohua ^a   Li, Boan ^b   Li, Xingwang ^a   Hou, Jun ^b   Qiao, Yong ^a   Zhang, Renwen ^a   Li, Xin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

AIDS progression; CD4? T; GP73; Highly active antiretroviral therapy; Serum viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GOLGI PROTEIN 73; MEMBRANE PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOASSAY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892771377     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2754-5     Document Type: Article

References (34)

1. Quinn TC, Overbaugh J (2005) HIV/AIDS in women: an expanding epidemic. Science 308:1582-1583
2. Yousaf MZ, Zia S, Babar ME, Ashfaq UA (2011) The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan. Virol J 8:401
3. Drannik AG, Henrick BM, Rosenthal KL (2011) War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 39:1427-1432
4. Deeks SG (2011) HIV: how to escape treatment. Nature 477:36-37
5. Puren A, Gerlach JL, Weigl BH, Kelso DM, Domingo GJ (2010) Laboratory operations, specimen processing, and handling for viral load testing and surveillance. J Infect Dis 201(Suppl 1):S27-S36
6. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kah-aruza F et al (2011) Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving anti-retroviral therapy in Uganda: randomised trial. BMJ 343:d6792
7. Nie T, Detorio M, Schinazi RF (2011) Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes. Antivir Ther 16:1267-1275
8. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV et al (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25:1753-1760
9. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Le-win SR (2011) Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 5:171-186
10. Lewin SR, Rouzioux C (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25:885-897
11. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ et al (2000) GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249:53-65
12. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S et al (2010) Golgi protein 73 (GOLPH2) is a valuable serum marker for hepato-cellular carcinoma. Gut 59:1687-1693
13. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ et al (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocel-lular carcinoma. Hepatology 41:634-642
14. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fim-mel CJ et al (2005) GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43:1007-1012
15. Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pest-alozzi BC et al (2009) Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 49:1602-1609
16. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R et al (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68:645-649
17. Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J (2008) GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 68:1387-1395
18. Zhang F, Gu Y, Li X, Wang W, He J, Peng T (2010) Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue. Clin Biochem 43:983-991
19. Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX (2011) Expression of the Golgi phosphoprotein-3 gene in human glio-mas: a pilot study. J Neurooncol 105:159-163
20. Fritzsche FR, Kristiansen G, Riener MO, Dietel M, Oelrich B (2010) GOLPH2 expression may serve as diagnostic marker in seminomas. BMC Urol 10:4
21. Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G (2008) GOLPH2 expression in renal cell cancer. BMC Urol 8:15
22. Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S et al (2011) A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat 10:287-294
23. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599
24. Shipley TW, Kling HM, Morris A, Patil S, Kristoff J, Guyach SE et al (2010) Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS. J Infect Dis 202:302-312
25. Vining DJ, Gladish GW (1992) Receiver operating characteristic curves: a basic understanding. Radiographics 12:1147-1154
26. De Milito A (2004) B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2:11-21
27. Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL (2011) A comparative evaluation of Golgi protein-73, fucosylated hemopexin, a-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 49:711-718
28. Athan E, O'Brien DP, Legood R (2010) Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings. AIDS 24:1887-1895
29. Bachert C, Fimmel C, Linstedt AD (2007) Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 8:1415-1423
30. Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X (2011) Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med 49:1311-1316
31. Hu JS, Wu DW, Liang S, Miao XY (2010) GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol 27:339-345
32. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H et al (2004) Disease-and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 99:1087-1095
33. Martin-Carbonero L, de Ledinghen V, Moreno A, Maida I, Foucher J, Barreiro P et al (2009) Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 16:790-795
34. Wright LM, Yong S, Picken MM, Rockey D, Fimmel CJ (2009) Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2:34-47